Mass spectrometric (HPLC/ESI--MS/MS) quantification of pyrimido[1,3-a]purin-10(3H)-one, a guanine adduct formed by reaction of malondialdehyde with DNA

A high performance liquid chromatography/electrospray ionization tandem mass spectrometric (HPLC/ESI MS/MS) method has been developed for quantification of pyrimido[1,2-a]purin-10(3H)-one adducts from DNA. The method is based on acid-catalyzed cleavage of the adducts from DNA and the use of [2,3a,10-13C3]pyrimido[1,2-a]purin-10(3H)-one as an internal standard in the analysis. For this purpose the latter compound was prepared. Rate constants for the acid-catalyzed cleavage of pyrimido[1,2-a]purin-10(3H)-one from the corresponding 2'-deoxyribonucleoside were determined, and its hydrolytic stability and possible formation by a cross reaction between guanine and [2,3a,10]pyrimido[1,2-a]purin-10(3H)-one were studied.     

Pyrimido[1,2-alpha]purin-10(3H)-one: a reactive electrophile in the genome

Malondialdehyde and base propenal react with deoxyguanosine residues in DNA to form an exocyclic adduct, pyrimido[1, 2-alpha]purin-10(3H)-one (1), that has been detected at high levels in genomic DNA of healthy humans. Previous studies have shown that tris(hydroxymethyl)aminomethane adds to 1 at elevated pH, forming an enaminoimine (2), but it is uncertain whether 1 reacts directly or hydrolyzes under basic conditions to N(2)-(3-oxo-1-propenyl)deoxyguanosine (3) prior to amine addition. We report that 1 reacts at neutral pH with hydroxylamines to form oximes. The rate of reaction of 1 with hydroxylamines at pH 7 is at least 150 times faster than the rate of hydrolysis of 1 to 3. Thus, 1 is directly reactive to nucleophiles. These observations indicate that 1 is an electrophile in the human genome that may react with cellular nucleophiles to form novel cross-linked adducts.     

Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones

The synthesis of a series of substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones is described. Several members of the series exhibit enhanced antiallergic and bronchodilator activity and reduced side effects as compared to theophylline. Structure-activity relationships and metabolic considerations are discussed for the series. Analogues substituted with a 4-(4-chlorobenzyl) moiety, such as 33 and 40, shown an optimal balance of antiallergic and bronchodilator activity and are of particular interest. Compound 33 is significantly more potent than theophylline against both metacholine- and antigen-induced bronchospasms, does not affect spontaneous motor activity, and shows minimal cardiovascular effects in the rat.     

Site specific synthesis and polymerase bypass of oligonucleotides containing a 6-hydroxy-3,5,6,7-tetrahydro-9H-imidazo[1,2-a]purin-9-one base, an intermediate in the formation of 1,N2-etheno-2'-deoxyguanosine

The reaction of DNA with certain bis-electrophiles such as chlorooxirane and chloroacetaldehyde produces etheno adducts. These lesions are highly miscoding, and some of the chemical agents that produce them have been shown to be carcinogenic in laboratory animals and in humans. An intermediate in the formation of 1,N2-ethenoguanine is 6-hydroxy-3,5,6,7-tetrahydro-9H-imidazo[1,2-a]purin-9-one (6-hydroxyethanoguanine), which undergoes conversion to the etheno adduct. The chemical properties and miscoding potential of the hydroxyethano adduct have not been previously studied. A synthesis of the hydroxyethano-adducted nucleoside was developed, and it was site specifically incorporated into oligonucleotides. This adduct had a half-life of between 24 and 48 h at neutral pH and 25 degrees C at the nucleoside and oligonucleotide levels. The miscoding potential of the hydroxyethano adduct was examined by primer extension reactions with the DNA polymerases Dpo4 and pol T7-, and the results were compared to the corresponding etheno-adducted oligonucleotide. Dpo4 preferentially incorporated dATP opposite the hydroxyethano adduct and dGTP opposite the etheno adduct; pol T7- preferentially incorporated dATP opposite the etheno adduct while dGTP and dATP were incorporated opposite the hydroxyethano adduct with nearly equal catalytic efficiencies. Collectively, these results indicate that the hydroxyethano adduct has a sufficient lifetime and miscoding properties to contribute to the mutagenic spectrum of chlorooxirane and related genotoxic species.     

Monitoring in vivo metabolism and elimination of the endogenous DNA adduct, M1dG {3-(2-deoxy-beta-D-erythro-pentofuranosyl)pyrimido[1,2-alpha]purin-10(3H)-one}, by accelerator mass spectrometry

Our laboratory is investigating the in vitro and in vivo metabolic processing of endogenously formed DNA adducts as a means of evaluating candidate urinary biomarkers. In particular, we have focused our studies on the metabolism and disposition of the peroxidation-derived pyrimidopurinone deoxyguanosine (dG) adduct, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)pyrimido[1,2-R]purin-10(3H)-one (M1dG), and its principal metabolite, 6-oxo-M1dG. We now report the metabolic processing of M1dG at concentrations 4-8 orders of magnitude lower in concentration than previously analyzed, by the use of accelerator mass spectrometry analysis. Administration of 2.0 nCi/kg [14C]M1dG resulted in 49% of the 14C recovered in urine, whereas 51% was recovered in feces. In urine samples, approximately 40% of the 14C corresponded to the metabolite, 6-oxo-M1dG. Following iv administration of 0.5 and 54 pCi/kg [14C]M1dG, approximately 25% of the urinary recovery corresponded to the metabolite, 6-oxo-M1dG. Thus, upon administration of trace amounts of M1dG, a significant percentage of 6-oxo-M1dG was produced, suggesting that 6-oxo-M1dG maybe a useful urinary marker of exposure to endogenous oxidative damage.     

Synthesis and pharmacological activity N-aryloxyethyl derivatives of 9H-2,3-dihydroimidazo-and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles

A series of N-aryloxyethyl derivatives of 9H-2,3-dihydroimidazo-and 10H-2,3,4,10-tetrahydropyrimido-[1,2-a]benzimidazoles have been synthesized and tested for pharmacological properties. It is established that most of the synthesized substances exhibit antiarrhythmic, antiaggregant and hemorheological activity. __________ Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 9, pp. 23–26, September, 2006.     

A modified immuno-enriched 32P-postlabeling method for analyzing the malondialdehyde-deoxyguanosine adduct, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)- pyrimido[1,2-alpha]purin-10(3H)one in human tissue samples

The malondialdehyde-modified DNA adduct, 3-(2-deoxy-beta-d-erythro-pentofuranosyl)pyrimido[1,2-alpha]purin-10(3H)one (M1dG) has been detected in human tissues and is considered to be a promising biomarker for estimating lipid peroxidation-induced DNA damage. With the aim to analyze the M1dG in small amounts of DNA (<10 microg) and to improve the sensitivity, we have developed an immuno-enriched 32P-postlabeling HPLC method. The main modifications included the following steps: (i) an optimization of the immunoenrichment conditions using a monoclonal antibody (MAb D 10A1), (ii) a single labeling step of the purified M1dG 3'-monophosphate to its 5'-monophosphate at pH 6.8, (iii) the addition of O4-ethylthymidine 3'-monophosphate as an internal standard, and (iv) a prepurification of the labeled adduct on a polyethyleneimine minicolumn before HPLC analysis. With this protocol, the percent recovery of M1dG was found to be approximately 70 +/- 20; the detection limit in biological samples was approximately 200 amol M1dG from 10 microg of DNA, corresponding to 6 adducts/10(9) nucleotides. In conclusion, our modified method shows a high sensitivity and specificity; when applied to human breast and liver tissue samples, background levels of the M1dG could be reproducibly detected. This ultrasensitive detection method is thus suitable for applications in human biomonitoring and molecular epidemiology studies.     

Synthesis of Ethyl 4(1H)-Oxopyrimido[1,2-a]perimidine-3-carboxylate

In a recent communication¹), we reported the synthesis of some biologically interesting 1-substituted 3-(2-perimidyl)- ureas starting from 2-aminoperimidine ( 1a ). Because of the presence of a 1,3-dinucleophilic center in this molecule, 1a might undergo cyclocondensation with appropriate dielectrophiles. So this compound might be a useful synthon for the generation of novel fused perimidine derivatives. In an orientation experiment, we found that the reaction of 1a HBr with dimethyl acetylenedicarboxylate in the presence of Et₃N proceeded smoothly and afforded methyl 4(1H)-oxopyrimido[1,2-a]perimidine-2-carboxylate 2a in 52% yield²). The structure ov 2a was assigned on the basis of spectral analysis.     

Thiophen als Strukturelement physiologisch aktiver Substanzen, 8. Mitt. 1H,5H-Imidazo[1,2-a]thieno[3,4-d]pyrimidin-2(3H)-one

Thiophene as a Structural Element of Physiologically Active Compounds, VIII: 1H,5H-Imidazo[1,2-a]thieno[3,4-d]pyrimidin-2(3H)-ones The tricyclic title compound 1 can be synthesized in one step from the thiophene compounds 13 or 17 by base induced twofold ring closure.     

2-(咪唑并[1, 2-a]吡啶-3-基)乙酸的合成工艺改进

目的 改进抗骨质疏松药米诺膦酸的关键中间体2-(咪唑并[1, 2-a]吡啶-3-基)乙酸的制备方法。方法 以2-氧代戊二酸二乙酯为起始原料,经溴代、环合、水解和脱羧4步反应制得目标产物。结果 目标化合物的熔点与¹H-NMR 谱数据与文献报道相符,总收率为40.5%(以2-氧代戊二酸二乙酯计)。结论 与文献报道的方法相比,改进后的工艺路线后处理简单,更有利于工业化生产。     

Hexahydroimidazo[1,5-a]pyrazine. I. Synthesis of 7-methyl-1,5,6,7,8a-hexahydroimidazo[1,5-a]pyrazin-3(2H)-one and derivatives]

The synthesis and pharmacological activity of a series of 2-aryl or alkyl substituted 7-methyl-1,5,6,7,8,8a-hexahydroimidaso[1,5-a]pyrazin-3(2H)-ones, are reported. The 2-aryl derivatives (VI) have been prepared by reaction of 3-(arylaminomethyl)-1-methylpiperazines (IV) have been prepared by reaction of 3-(arylaminomethyl)-1-methylpiperazines (IV) with N,N'-carbonyldiimidazole. Reaction of various anilines with 3-carbomethoxy-1-methylpiperazine (II) and subsequent reduction of the amides (III) afforded the bases (IV). The synthesis of the unsubstituted compound (XII) has been accomplished either by cyclization with sodium methoxide of methyl (1-me-thylpiperazin-3-yl)methylcarbamate (XI) or by reaction of 3-aminomethyl-1-methylpiperazine (XV) with N,N'-carbonyldiimidazole. Reduction of 1-benzyl-2-cyano-4-methylpiperazine (VII) followed by reaction with methyl chloroformate and debenzylation afforded the urethane (XI). The 2-alkyl and 2-alkenyl derivatives (XIII) have been prepared by alkylation of the sodium salt of (XII) in DMF. The compounds of these series have been tested for antiinflammatory, coronary dilator and C.N.S. depressant activities.     

Synthetic transformation of 6-Fluoroimidazo[1,2-a]Pyridine-3-carbaldehyde into 6-Fluoroimidazo[1,2-a]Pyridine-Oxazole Derivatives: In vitro urease inhibition and in silico study

PurposeUlcer is a serious disease that is caused due to different bacteria and over usage of various NSAIDs which caused to reduce the defensive system of stomach. Therefore, some novel series are needed to overcome these issues.MethodsOxazole-based imidazopyridine scaffolds (4a-p) were designed and synthesized by two step reaction protocol and then subjected to urease inhibition profile (in vitro). All the newly afforded analogs (4a-p) were found potent and demonstrated moderate to significant inhibition profile.ResultsParticularly, the analogs 4i (IC₅₀ = 5.68 ± 1.66 μM), 4o (IC₅₀ = 7.11 ± 1.24 μM), 4 g (IC₅₀ = 9.41 ± 1.19 μM) and 4 h (IC₅₀ = 10.45 ± 2.57 μM) were identified to be more potent than standard thiourea drug (IC₅₀ = 21.37 ± 1.76 μM). Additionally, the variety of spectroscopic tools such as ¹H NMR, ¹³C NMR and HREI-MS analysis were employed to confirm the precise structures of all the newly afforded analogs.DiscussionThe structure–activity relationship (SAR) studies showed that analogs possess the substitution either capable of furnishing strong HB like –OH or had strong EW nature such as -CF₃ & –NO₂ groups displayed superior inhibitory potentials than the standard thiourea drug. A good PLI (protein–ligand interaction) profile was shown by most active analogs when subjected to molecular study against corresponding target with key significant interactions such as pi-pi stacking, pi-pi T shaped and hydrogen bonding.     

Regioselective synthesis of [1]benzopyrano[4,3-c]pyrazol-4-(1H)-one and [1]benzopyrano[3,4-c]pyrazol-4(3H)-one derivatives

The cycloaddition reaction of N-phenyl-C-cinnamonitrilimine4 to coumarin leads to the formation of 3-styrylbenzopyrano[4,3-c]pyrazole derivative6, whereas 3-phenylsulfonylcoumarin 0163 0181 V 39 or 3-bromocoumarin10 or 3-cyanocoumarin11 gives 1-styrylbenzopyrano[3,4-c]pyrazole derivative7. Also, the cycloaddition of4 to 3-acetylcoumarin15 and 3-benzoylcoumarin16 gives the corresponding dihydropyrano[3,4-c]pyrazole adducts17 and18 respectively. Oxidation of17 and18 gives7.     

6-aminopyrazolo[4,3-c]pyridin-4(5H)-one, a novel analogue of guanine.

Treatment of dimethyl alpha-ethoxymethylidineacetonedicarboxylate with hydrazine gave methyl 3-(methoxy-carbonylmethyl)pyrazole-4-carboxylate which, upon ammonolysis and dehydration, afforded methyl 3-(cyanomethyl)pyrazole-4-carboxylate. This compound, when heated with liquid ammonia, gave 6-aminopyrazolo[4,3-c]pyridin-4(5H)-one, a new guanine analogue, which did not possess any of the potent antiviral activity shown by 6-aminoimidazo[4,5-c]pyridin-4(5H)-one (3-deazaguanine).     

Anti-histaminic, anti-inflammatory and bronchorelaxant activities of 2, 7-dimethyl-3-nitro-4H pyrido [1,2-a] pyrimidine-4-one

An immunopharmacological profile of 2, 7-dimethyl-3-nitro-4H pyrido [1,2-a] pyrimidine-4-one (P-I) has been investigated using in vitro and in vivo models representing various features of Type I allergy. P-I prevented compound 48/80-mediated histamine release from rat peritoneal mast cells. A promising anti-inflammatory activity of P-I was evident in active paw anaphylaxis (mice) and carragenan-induced paw edema (rat). P-I inhibited eosonophil accumulation and eosinophil peroxidase activity in bronchoalveolar lavage fluid from ovalbumin challenged balb/c mice: in these animals blood levels of IL-5, and CD4+ T cells also remained attenuated. A promising bronchorelaxant effect of P-I was observed in histamine-contracted guinea pig tracheal chain via its antagonism to H1 receptor. These findings were compared with some known compounds (ketotifen, cetirizine and promethazine). The anti-histaminic, anti-inflammatory and bronchorelaxant activities of P-I has been discussed in context with its potential profile as an anti-allergic and anti-asthmatic agent.     

Synthesis of substituted 3-hydroxy-1H,5H-pyrido[1,2-a]benzimidazol-1-ones as possible antimicrobial and antineoplastic agents

Syntheses of the title compounds 3 as possible antimicrobial and antineoplastic agents were achieved by reacting the active malonates 1 with the benzimidazoles 2a,b . On the other hand, reaction of 1c,d with 2-methylbenzimidazole (2c) yielded the imidazoquinolinones 4a,b . Four compounds in the series 3 displayed in vitro antibacterial and antifungal activities.     

Synthesis and biological activity of N-acylmethyl derivatives of 9H-2,3-dihydroimidazo-and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles and their reduction products

A series of N-acylmethyl derivatives of 9H-2,3-dihydroimidazo-and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles and products of their reduction has been synthesized and their pharmacological properties have been studied. Most of the synthesized substances possess weak antioxidant activity. At the same time, they exhibit pronounced antiaggregant and hemorheological properties, possess spasmolytic activity, and influence the blood glucose level. __________ Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 5, pp. 27–33, May, 2006.